A hit is a real, reproducible starting point
A hit is a molecule that shows measurable, reproducible activity against your target in a well-behaved assay. That is all it has to be at first: something that binds or inhibits or activates, above the noise, more than once. It does not need to be potent, selective, soluble, or safe — those properties come later. The whole point of screening is to find honest starting points so chemists have something concrete to improve.
The distinction worth holding onto is hit versus lead. A hit is raw — often weak, often dirty. A lead has survived confirmation, shows a believable structure–activity relationship, and has properties good enough that you would invest months optimizing it. Most hits never become leads, and that is normal. Screening is a numbers game played to find the few that will.
Where hits come from
There is no single road to a hit. The major routes each suit different situations. High-throughput screening runs a large physical library against the target one compound per well. Fragment-based discovery starts from very small molecules that bind weakly but efficiently. Virtual screening uses computers to triage millions of compounds before anyone touches a pipette. DNA-encoded libraries pool billions of compounds, each tagged with a DNA barcode, into a single tube.
Which route you pick depends on the target and what you already know. A well-characterized enzyme with a crisp active site is friendly to fragments and structure-guided design. A target where you only know the biology, not the binding site, often calls for phenotypic screening in cells. Good teams frequently run more than one approach in parallel, because each pulls a different slice of chemical space.
The honest gap between a hit and a drug
It helps to feel the scale. A campaign might test a million compounds, flag a few thousand as active, confirm a few hundred, cluster those into a handful of chemical series, and carry maybe two or three series into lead optimization. From there, years of medicinal chemistry separate a confirmed bioactivity from a drug. The screen is the very first filter in a long, lossy funnel — vital, but only a beginning.